Portfolio: Life Sciences
BioRexis Pharmaceutical Corp (acquired by Pfizer)
BioRexis' proprietary protein engineering technology provides novel protein and peptide drugs with superior pharmacology and Trans-bodies™ to replace conventional monoclonal antibodies. BioRexis' technology involves fusion of peptides and proteins to a modified version of the blood serum protein transferrin, thereby prolonging their circulatory half-life, reducing dosage, improving efficacy and decreasing side effects. The company's lead product is a peptide fusion, currently in preclinical trials for Type 2 diabetes.
Insulet Corporation (IPO)
Founded in August 2000, Insulet Corporation, located in Bedford, MA, is an innovative medical device company dedicated to designing and developing products that provide superior treatment options and lifelong health benefits for people with diabetes. This system can also provide benefits for those requiring large protein molecule drug delivery. Insulet's unique insulin delivery system builds upon the safety and reliability of today's insulin pumps, while incorporating new technology and features that offer unprecedented operational performance, simplicity and cost savings. Diabetes is a chronic, life-threatening disease characterized by the failure of the body to produce or properly utilize insulin, a hormone that regulates blood glucose. In the United States alone, an estimated 17 million people have diabetes, with nearly 800,000 new cases diagnosed each year. Worldwide, more than 177 million people have diabetes, and the World Health Organization expects the number of cases to reach 300 million by the year 2025.
Serica Technologies, Inc. (acquired by Allergan)
Serica Technologies, Inc., formerly Tissue Regeneration, Inc., is a growth-stage medical device company pioneering silk-based biomaterial platforms for tissue rejuvenation. Incorporated in 1998, Serica’s proprietary products currently in preclinical and clinical development are being studied in the areas of orthopedic and sports medicine, aesthetic and reconstructive plastic surgery and other structural tissue repair needs. Serica’s team of engineers and scientists are located in a state-of–the-art 22,000-square-foot office, R&D and manufacturing facility in Medford, MA.
